Filter results
You can narrow down the results using the filters
Topic
- (-) COVID-19 vaccines (64)
- Advertising (203)
- COVID-19 (112)
- Medicines safety (89)
- Prescription medicines (62)
- Regulatory compliance (60)
- Medicines (49)
- Medical devices safety (34)
- Legislation (31)
- Medical devices (29)
- Listed medicines (25)
- Non-prescription medicines (22)
- Manufacturing (19)
- Assessed listed medicines (18)
- Scheduling (17)
- Complementary medicines (16)
- Unapproved therapeutic goods (14)
- Safety (12)
- Therapeutic goods regulation (12)
- Medicinal cannabis hub (10)
- OTC medicines (10)
- Shortages (10)
- Labelling and packaging (9)
- Nicotine vaping products hub (9)
- Sunscreens (7)
- Biologicals (6)
- Import and export (6)
- Australian Register of Therapeutic Goods (ARTG) (5)
- Alert/Advisory (4)
- Compliance and enforcement hub (3)
- Advisory bodies and committees (2)
- Fees and payments (2)
- In Vitro Diagnostic medical devices (IVDs) (2)
- Weight loss products (2)
- Biological medicines (1)
- Blood and blood components (1)
- Blood safety (1)
- Clinical trials (1)
- Cosmetics (1)
- Other therapeutic goods (1)
- Prescription opioids hub (1)
- Travelling with health products (1)
- Unique Device Identification (UDI) Hub (1)
Search
64 result(s) found, displaying 1 to 25
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 23-03-2023Information about the TGA's safety monitoring of COVID-19 vaccines.
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 09-03-2023Information about the TGA's safety monitoring of COVID-19 vaccines.
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 23-02-2023Information about the TGA's safety monitoring of COVID-19 vaccines.
- Media releasesTGA grants provisional approval to Moderna’s COVID-19 bivalent (SPIKEVAX Bivalent Original/Omicron BA.4-5) booster dose vaccineOn 17 February, the TGA granted provisional approval to Moderna’s bivalent COVID-19 vaccine. This is the second bivalent vaccine targeting the Omicron BA.4-5 subvariants that has been provisionally approved by the TGA
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 09-02-23Information about the TGA's safety monitoring of COVID-19 vaccines.
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 27-01-2023Information about the TGA's safety monitoring of COVID-19 vaccines.
- Media releasesTGA grants provisional approval to Pfizer’s COVID-19 bivalent (COMIRNATY Original/Omicron BA.4-5 COVID-19 vaccine) booster dose vaccineThis is the first vaccine provisionally approved by the TGA that is designed to specifically target the Omicron variants BA.4/BA.5 and follows provisional approval of the Pfizer BA.1 Omicron/original bivalent vaccine.
- Media releasesTGA commences evaluation of Moderna COVID-19 vaccine (SPIKEVAX) for potential transition to full registrationThe TGA has commenced evaluation of an application from Moderna Australia Pty Ltd to transition its COVID-19 vaccine, SPIKEVAX, to full registration for the immunisation of individuals 6 years and over, and as a booster dose for individuals aged 12 years and older.
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report – 12-01-2023Information about the TGA's safety monitoring of COVID-19 vaccines.
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 22-12-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 15-12-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 01-12-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 17-11-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- Media releasesTGA grants provisional determination to Pfizer’s COVID-19 bivalent (COMIRNATY BIVALENT OMICRON BA.4/BA.5) booster dose vaccineThe TGA has granted a provisional determination to Pfizer's bivalent COVID-19 vaccine candidate: tozinameran & famtozinameran (COMIRNATY BIVALENT OMICRON BA.4/BA.5 COVID-19 VACCINE).
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 03-11-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- COVID-19 vaccine safety reportsCOVID-19 vaccine weekly safety report - 09-06-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- Media releasesTGA provisionally approves Pfizer bivalent COVID-19 vaccine for use as a booster dose in adultsThe TGA has provisionally approved Pfizer’s bivalent COVID-19 vaccine, tozinameran and riltozinameran (COMIRNATY Original/Omicron BA.1) for use as a booster dose in adults 18 years and over.
- Media releasesTGA provisionally approves Moderna’s COVID-19 vaccine for use as a booster dose in individuals 12 years and olderOn 19 October 2022, the TGA provisionally approved Moderna's COVID-19 vaccine, SPIKEVAX (elasomeran), for use as a booster dose in individuals aged 12 years and older.
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 20-10-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 06-10-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- Media releasesTGA grants provisional determination to Moderna’s COVID-19 bivalent (Original plus Omicron BA.4/BA.5) booster dose vaccineThe TGA has granted a provisional determination to Moderna Australia Pty Ltd’s bivalent COVID-19 vaccine candidate: elasomeran and davesomeran (SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4/BA.5)
- Media releasesTGA provisionally approves Pfizer’s COVID-19 vaccine, COMIRNATY (tozinameran) for use in children aged 6 months to less than 5 yearsThe TGA has provisionally approved a paediatric dose of Pfizer’s COVID-19 vaccine, COMIRNATY (tozinameran), for children aged 6 months to less than 5 years
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 23-09-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- Media releasesTGA provisionally approves Pfizer's COVID-19 vaccine, COMIRNATY (tozinameran), for use as a booster dose in individuals 5 years and olderThe TGA has provisionally approved Pfizer's COVID-19 vaccine, COMIRNATY (tozinameran) for use as a booster dose in individuals 5 years to 11 years.
- COVID-19 vaccine safety reportsCOVID-19 vaccine safety report - 08-09-2022Information about the TGA's safety monitoring of COVID-19 vaccines.